Bloomberg @business
A company that helped pioneer genetic tests used to diagnose and treat disease lost more than 40% of its value Wednesday, after U.S. regulators questioned whether a DNA test can help personalize the prescribing of antidepressants https://t.co/RtrgbBTR9g — PolitiTweet.org